The Middle East and Asia Pacific Biotechnology Market is Poised to Witness High Growth due to Rising Healthcare Expenditure

The Middle East and Asia Pacific biotechnology market includes medical device manufacturing companies engaged in developing surgical equipment and devices for minimally invasive surgeries and other procedures. Minimally invasive devices are gaining popularity owing to benefits such as smaller incisions, less pain, shorter hospital stays, and quicker recovery times compared to traditional open surgeries. These devices are broadly utilized across therapeutic applications like gynecology, urology, orthopedic, cardiology, gastroenterology, and others.

The global Middle East and Asia Pacific biotechnology market is estimated to be valued at US$ 328.64 million in 2024 and is expected to exhibit a CAGR of 7.2% over the forecast period of 2024 to 2030.

 Rising healthcare expenditure of countries in the Middle East and Asia Pacific region is driving the demand for improved healthcare services and advanced treatment options such as minimally invasive surgeries requiring biotechnology devices.

Key Takeaways
Key players operating in the Middle East and Asia Pacific biotechnology market are Medtronic plc, CONMED Corporation, Ethicon, Inc., Symmetry Surgical Inc., B. Braun Melsungen AG, Olympus Corporation, Erbe Elektromedizin GmbH, Innoblative Designs, Inc., Stryker Corporation, OmniGuide Inc., and PENTAX Medical. These players are focusing on new product development and launches to expand their product portfolios.

The key opportunities in the market include growing demand for minimally invasive treatments in orthopedics and cardiology. There is a rising preference for utilizing biotechnology devices owing to advantages like reduced scars, lower risks of surgical site infections, shorter hospital stay, and faster recovery.

The major players are expanding their presence globally through organic and inorganic growth strategies like acquisitions, collaborations and partnerships with hospitals and healthcare organizations. This allows them to penetrate new regional markets and enhance their geographic footprints across Middle East and Asia Pacific.

Market Drivers and Restraint

Some of the major drivers fueling the growth of The Middle East And Asia Pacific Biotechnology Market include rising prevalence of chronic diseases necessitating surgical treatments, increasing healthcare spending of governments in the region, and surging demand for advanced medical technologies.

However, factors like high costs associated with minimally invasive surgeries, dearth of skilled medical professionals, and lack of strong reimbursement policies in some developing nations are restraining the market growth. Also, uncertainties over regulatory approvals and stringent regulatory frameworks of different countries adds to the challenges faced by industry players.

Segment Analysis
Middle East and Asia Pacific biotechnology market is dominated by medical devices segment with around 40% market share in 2024. The medical devices segment comprises surgical equipment, medical robotics and computer-assisted surgical systems. The extensive use of surgical equipment for various procedures such as orthopedic, cardiovascular, neurosurgery and cosmetic surgeries has led to the large market share of medical devices segment. Further, the rising demand for minimally invasive surgeries along with growing adoption of robot-assisted technologies such as da Vinci surgical system is fueling the growth of this segment in the region.

The biopharmaceuticals segment is the fastest growing segment owing to the high prevalence of chronic diseases and increasing demand for healthcare. Biopharmaceuticals include monoclonal antibodies, cytokines, growth factors and recombinant therapeutic proteins. Monoclonal antibodies segment accounts for over 30% of biopharmaceuticals segment due to growing applications in cancer, autoimmune and infectious diseases treatment.

Global Analysis
Asia Pacific region dominates the Middle East and Asia Pacific biotechnology market with around 65% share in 2024 on account of large patient pool, increasing healthcare spending, rising number of biotechnology companies and growing public-private investments. Within Asia Pacific region, China is expected to witness the fastest growth during the forecast period attributed to improving healthcare infrastructure, favorable government policies to boost domestic manufacturing and emerging contract research organizations (CROs) fuelling outsourcing activities.

The Middle East region is projected to grow at a CAGR of over 9% during the forecast period backed by surging demand for immunotherapies, cell therapies and genetically modified crops. In addition, growing public-private alliances focusing on research collaborations and technology transfers are aiding the growth of biotechnology sector in the Middle East region.

Get more insights on this topic:

https://www.newsstatix.com/middle-east-and-asia-pacific-biotechnology-market-demand/